Drug allergy: Clinical aspects, diagnosis, mechanisms, structure-activity relationships

Drug Allergy: Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships

Volumn 9781461472612, Issue , 2013, Pages 1-447

  Baldo, Brian A ^a   Pham, Nghia H ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930448238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7261-2     Document Type: Book

References (215)

1. Baldo BA, McDonnell NJ, Pham NH. Drug-specific cyclodextrans with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy. Clin Exp Allergy. 2011;41:1663-78.
2. Barone C, Mousa SS, Mousa SA. Pharmacogenomics in cardiovascular disorders: steps in approaching personalized medicine in cardiovascular medicine. Pharmgenomics Pers Med. 2009;2:59-67.
3. Bharadwaj M, Illing P, Theodossis E, et al. Drug hyper-sensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401-31.
4. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol. 2012;52:21-35.
5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356: 1255-9.
6. Landsteiner K. The specificity of serological reactions. New York: Dover; 1962.
7. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med. 1935;61:643-56.
8. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds II. J Exp Med. 1936;64:625-39.
9. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13:1-9.
10. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA. 2001;286:2270-9.
11. Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. In: Davies DM, Ferner ER, de Glanville H, editors. Davies' textbook of adverse drug reactions. 5th ed. London: Chapman and Hall Medical; 1998. p. 40-64.
12. Talbot J, Aronson JK, editors. Stephen's detection and evaluation of adverse drug reactions. 6th ed. Chichester: Wiley-Blackwell; 2012.
13. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6:904-16.
14. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580-7.
15. Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program. 2004;63-79.
16. Bock G, Goode J, editors. Anaphylaxis. Novartis foundation symposium 257. Chichester: Wiley; 2004.
17. Castells MC, editor. Anaphylaxis and hypersensitivity reactions. New York, NY: Humana; 2011.
18. Grattan CE, Charlesworth EN. Urticaria. In: Holgate ST, Church M, Lichtenstein LM, editors. Allergy. 3rd ed. Philadelphia, PA: Mosby; 2006. p. 95-106.
19. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39-49.
20. Johansen JD, Frosch PJ, Lepoittevin J-P, editors. Contact dermatitis. Heidelberg: Springer; 2011.
21. Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter. Part I. Acute urticaria/angioedema. Part II. Chronic urticaria/angioedema. Ann Allergy Asthma Immunol. 2000;85:521-44.
22. Lieberman P. Definition and criteria for the diagnoses of anaphylaxis. In: Castells MC, editor. Anaphylaxis and hypersensitivity reactions. New York, NY: Humana; 2011. p. 1-12.
23. Litt JZ. Drug eruption reference manual. 12th ed. London: Taylor and Francis; 2006.
24. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.
25. Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12-7.
26. Salama A, Schutz B, Kiefel V, et al. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol. 1989;72:127-32.
27. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115:584-91.
28. Schön MP, Boehncke W-H. Psoriasis. N Engl J Med. 2005;352:1899-912.
29. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9:316-21.
30. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among Herpes viruses and antiviral and antidrug immune responses. Allergol Int. 2006;55:1-8.
31. Sidoroff A, Halevy S, Bavinck JNB, et al. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol. 2001;28:113-9.
32. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci. 2010;115:307-21.
33. 4 puzzle: Finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol. 2009;124:406-14.
34. Bäch M, Dahlėn E, Drazen JM, et al. International union of basic and clinical pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011;63:539-84.
35. Baldo BA. Immunochemical perspectives of allergy: in the steps of Karl Landsteiner. In: Baldo BA, editor. Monographs in allergy, Molecular approaches to the study of allergens, vol. 28. Basel: Karger; 1990. p. 1-10.
36. Baldo BA, Pham NH. Structure-activity studies on drug-induced anaphylactic reactions. Chem Res Toxicol. 1994;7:703-21.
37. Baldo BA, Smal MA, McCaskill C. A specific, sensitive and high-capacity immunoassay for PAF. Lipids. 1991;26:1136-9.
38. Bharadwaj M, Illing P, Kostenko L. Personalized medicine for HLA-associated drug-hypersensitivity reactions. Pers Med. 2010;7:495-516.
39. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy. 2008;38:4-18.
40. Cauwels A, Janssen B, Buys E, et al. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest. 2006;116:2244-51.
41. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28:822-32.
42. Chung W-H, Hung S-I, Yang J-Y, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343-50.
43. Cooper AM, Hobson PS, Jutton MR, et al. Soluble CD23 controls IgE synthesis and homeostasis in human B cells. J Immunol. 2012;188:199-207.
44. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120:506-15.
45. Frenzel DF, Weiss JM. Osteopontin and allergic disease: pathophysiology and implications for diagnosis and therapy. Expert Rev Clin Immunol. 2011;7:93-109.
46. Gaga M, Frew AJ, Varney VA, et al. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol. 1991;147:816-22.
47. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009;2009:73-9.
48. Gilfillan AM, Tkaczyk C. Integrated signaling pathways for mast-cell activation. Nat Rev Immunol. 2006;6:218-30.
49. Goncalo M, Bruynzeel DP. Mechanisms in cutaneous drug hypersensitivity reactions. In: Zhai H, Wilhelm K-P, Maibach HI, editors. Marzulli and Maibach's dermatotoxicology. 7th ed. Boca Raton, FL: CRC Press; 2008. p. 259-68.
50. Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol. 2003;21:579-628.
51. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol. 2007;33:134-43.
52. Homy B, Alenius H, Müller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157-65.
53. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486:554-8.
54. Kanaoka Y, Boyce J. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004;173:1503-10.
55. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133:309-14.
56. Olivera A, Mizugishi K, Tikhonova A, et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity. 2007;26:287-97.
57. Reiter E, Ahn S, Shukla AK, et al. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012;52:179-97.
58. Rivera J, Olivera A. Src family kinases and lipid mediators in control of allergic inflammation. Immunol Rev. 2007;217:255-68.
59. Romagnoli P, Labhardt AM, Sinigaglia F. Selective interaction of Ni with an MVC-bound peptide. EMBO J. 1991;10:1303-6.
60. Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1-13.
61. Schön MP, Boehncke W-H. Psoriasis. N Engl J Med. 2005;352:1899-912.
62. Shahid M, Tripathi T, Sobia F, et al. Histamine, histamine receptors, and their role in immunomodulation: an updated systematic review. Open Immunol J. 2009;2:9-41.
63. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2000;53:357-79.
64. 2+ to TCR/MHC contact sites in nickel-specific human T cell activation. J Immunol. 2004;172:1926-34.
65. Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358:79-81.
66. Valent P. Basophil activation antigens: molecular mechanisms and clinical implications. Open Allergy J. 2010;3:52-9.
67. Wei C-Y, Chung W-H, Huang H-W, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129:1562-9.
68. Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol. 2009;5:e1000441.
69. Aberer W, Kränke B. Provocation tests in drug hypersensitivity. Immunol Allergy Clin North Am. 2009;29: 567-84.
70. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209-16.
71. Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am. 2009;29:517-35.
72. Barbaud A, Gonçalo M, Bruynzeel D, et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45:321-8.
73. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100 Suppl 3:S66-S121.
74. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013; doi: 10.1111/all.12142.
75. Kalyuzhny AE, editor. Handbook of ELISPOT. Methods and protocols. Methods in molecular biology, vol. 792. New York: Human; 2012.
76. Lachapelle JM, Maibach HI Patch testing and prick testing. A practical guide. Berlin: Springer; 2003.
77. Laroche D, Dubois F, Gérard J-L, et al. Radioimmunoassay for plasma histamine: a study of false positive and false negative values. Br J Anaesth. 1995;74: 430-7.
78. Matsson PNJ, Hamilton RG, Esch RE, et al Analytical performance characteristics and clinical utility of immunological assays for human immunoglobulin E (IgE) antibodies and defined allergen specificities; approved guidelines-second edition. CLSI document I/LA20-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
79. NCCLS. (2004). Protocols for determination of limits of detection and limits of quantitation: approved guideline. NCCLS document EP17-A. NCCLS, Wayne, PA
80. Santamaria Babi LF, Picker LJ, Perez Soler MT, et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med. 1995;181:1935-40.
81. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26:451-63.
82. Schwartz LB, Min H-K, Ren S, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-Mac-6 cells, and human skin-derived mast cells. J Immunol. 2003;170:5667-73.
83. Söderstrom L, Kober A, Ahlstedt S, et al. A further evaluation of the clinical use of specific IgE antibody testing in allergic diseases. Allergy. 2003;58:921-8.
84. Steiner M, Harrer A, Lang R, et al. Basophil activation test for investigation of IgE-mediated mechanisms in drug hypersensitivity. J Vis Exp. 2011;55:e3263. doi:10.3791/3263.
85. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-77.
86. Baldo BA, Pham NH, Weiner J. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J Mol Recognit. 1995;8:171-7.
87. ∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41: 816-9.
88. Dewdney JM. Immunology of the antibiotics. In: Sela M, editor. The antigens, vol. 4. New York, NY: Academic; 1977. p. 73-228.
89. De Weck AL. Penicillins and cephalosporins. In: De Weck AL, Bundgaard H, editors. Allergic reactions to drugs, Handbook of experimental allergology. Berlin: Springer; 1983. p. 423-82.
90. Faraci WS, Pratt RF. Elimination of a good leaving group from the 3'-position of a cephalosporin need not be concerted with β-lactam ring opening: TEM-2 β-lactamase-catalysed hydrolysis of pyridine-2-azo-4'-(N',N'-dimethylaniline) cephalosporin (PADAC) and of cephaloridine. J Am Chem Soc. 1984;106: 1489-90.
91. Hamilton-Miller JMT, Newton GGF, Abraham EP. Products of aminolysis and enzymic hydrolysis of the cephalosporins. Biochem J. 1970;116:371-84.
92. Harle DG, Baldo BA. Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy. Mol Immunol. 1990;27:1063-71.
93. Levine BB. Immunochemical mechanisms of drug allergy. In: Miescher PA, Muller-Eberhard HJ, editors. Textbook of immunopathology, vol. 2. 2nd ed. New York, NY: Grune and Stratton; 1976. p. 403-19.
94. Montanez MI, Mayorga C, Torres MJ, et al. Synthetic approach to gain insight into antigenic determinants of cephalosporins: in vitro studies of chemical structure-IgE molecular recognition relationships. Chem Res Toxicol. 2011;24:706-17.
95. Parker CW. Drug allergy. In: Parker CW, editor. Clinical immunology, vol. 2. Philadelphia, PA: Saunders; 1980. p. 1219-60.
96. Pham NH, Baldo BA. β-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. J Mol Recognit. 1996;9:287-96.
97. Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol. 2010;126:994-9.
98. Romano A, Guéant-Rodriguez RM, Viola M, et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy. 2005;35:1234-42.
99. Salkind AR, Cuddy PG, Foxworth JW. The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA. 2001;285:2498-505.
100. Zhao Z, Baldo BA, Baumgart KW, et al. Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects. J Mol Recognit. 2001;14:300-7.
101. Zhao Z, Batley M, D'Ambrosio C, et al. In vitro reactivity of penicilloyl and penicillanyl albumin and polylysine conjugates with IgE-antibody. J Immunol Methods. 2000;242:43-51.
102. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol. 2010;125: 411-8.
103. Cribb AE, Miller M, Leeder JS, et al. Reactions of the nitroso and hydroxylamine metabolites of sulfa-methoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos. 1991; 19:900-6.
104. Cribb AE, Lee BL, Trepanier LA, et al. Adverse reactions to sulfonamide and sulfonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996;15:9-50.
105. Harle DG, Baldo BA, Wells J V. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol. 1988;25:1347-54.
106. Lerner A, Dwyer JM. Desensitization to vancomycin. Ann Intern Med. 1984;100:157.
107. Lim KS, Kam PCA. Chlorhexidine - pharmacology and clinical applications. Anaesth Intensive Care. 2008;36:502-12.
108. Parkes AW, Harper N, Herwadkar A, Pumphrey R. Anaphylaxis to chlorhexidine component of Instillagel®: a case series. Br J Anaesth. 2009;102:65-8.
109. Pham NH, Weiner JM, Reisner GS, Baldo BA. Anaphylaxis to chlorhexidine. Case report. Implication of immunoglobulin E antibodies and identification of an allergenic determinant. Clin Exp Allergy. 2000;30:1001-7.
110. Sahai J, Healy DP, Shelton MJ, et al. Comparison of van-comycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrob Agents Chemother. 1990;34:765-9.
111. Sheth VM, Weitzul S. Postoperative topical antimicrobial use. Dermatitis. 2008;19:181-9.
112. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349: 1628-35.
113. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2000;53:357-79.
114. Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother. 2001; 35:1458-64.
115. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature. 1983a;306:262-4.
116. Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: Cross-reactivity and molecular basis of binding of IgE antibodies detected by radioimmunoassay. Mol Immunol. 1983b;20:1393-400.
117. Baldo BA, Fisher MM. Diagnosis of IgE-dependent anaphylaxis to neuromuscular blocking drugs, thiopentone and opioids. Ann Fr Anesth Reanim. 1993;12:173-81.
118. Baldo BA, Fisher MM, Pham NH. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. Clin Exp Allergy. 2009;39:325-44.
119. Baldo BA, McDonnell NJ, Pham NH. The cyclodextrin sugammadex and anaphylaxis to rocuronium: is rocuronium still potentially allergenic in the inclusion complex form? Mini Rev Med Chem. 2012;12: 701-12.
120. Ewan PW, Dugue P, Mirakian R, et al. BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia. Clin Exp Allergy. 2009;40: 15-31.
121. Fisher MM, Baldo BA. Anaphylaxis during anaesthesia: current aspects of diagnosis and prevention. Eur J Anaesthesiol. 1994;11:263-84.
122. Fisher MM, Baldo BA. Immunoassays in the diagnosis of anaphylaxis to neuromuscular blocking drugs: the value of morphine for the detection of IgE antibodies in allergic subjects. Anaesth Intensive Care. 2000;28: 167-70.
123. Florvaag E, Johansson SGO. The pholcodine story. Immunol Allergy Clin North Am. 2009;29:419-27.
124. Fuzier R, Lapeyre-Mestre M, Mertes PM, et al. Immediate-and delayed-type allergic reactions to amide local anesthetics: clinical features and skin testing. Pharmacoepidemiol Drug Saf. 2009;18:595-601.
125. Harle DG, Baldo BA, Fisher MM. The molecular basis of IgE antibody binding to thiopentone. Binding of IgE from thiopentone-allergic and non-allergic subjects. Mol Immunol. 1990;27:853-8.
126. Harper NJN, Dixon T, Dugue P, et al. Guidelines. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia. 2009;64:199-211.
127. Kroigaard M, Garvey LH, Gillberg L, et al. Scandinavian clinical practice guidelines on the diagnosis, management and follow-up of anaphylaxis during aneasthesia. Acta Anaesthesiol Scand. 2007;51:655-7.
128. Levy JH. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg. 2008;106: 392-403.
129. Mertes PM, Alla F, Trechot P, et al. Anaphylaxis during anesthesia in France: an 8-year national survey. J Allergy Clin Immunol. 2011a;128:366-73.
130. Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011b;21:442-53.
131. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care. 2012;40:216-35.
132. Casy AF, Parfitt RT Opioid analgesics. Chemistry and receptors. New York, NY: Plenum Press; 1986.
133. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev. 2004;24: 182-212.
134. Freye E. Opioids in medicine. Dordrecht: Springer; 2008.
135. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879-923.
136. Portoghese PS. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem. 2001;44:2259-69.
137. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11:S133-53.
138. Wu Z, Hruby VJ. Backbone alignment modeling of the structure-activity relationships of opioid ligands. J Chem Inf Model. 2011;51:1151-64.
139. Yaksh TL, Wallace MS. Opioids, analgesia and pain management. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New York, NY: McGraw Hill; 2011. p. 481-526.
140. Berges-Gimeno MP, Simon RA, Stevenson DD. Longterm treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111:180-6.
141. Harris RE, editor. Inflammation in the pathogenesis of chronic diseases. The COX-2 controversy. Subcellular Biochemistry, vol. 42. New York: Springer; 2007.
142. Higashi N, Taniguchi M, Mita H, et al. Aspirin-intolerant asthma (AIA). Assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int. 2012;61:393-403.
143. Kim S-H, Ye Y-M, Lee S-K, et al. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol. 2006;6:266-70.
144. Kowalski ML, Ptasinska A, Jedrzejczak M, et al. Aspirintriggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive aspirin-sensitive patients identification test (ASPITest). Allergy. 2005; 60:1139-45.
145. Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy. 2011;66:818-29.
146. Palikhe NS, Kim S-H, Jin HJ et al. (2012) Genetic mechanisms in aspirin-exacerbated respiratory disease. J Allergy (Cairo). Article ID 794890, 6 pages doi. 10.1155/2012/794890.
147. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. The multiple faces of nonsteroiod antiinflammatory drug hypersensitivity. J Investig Allergol Clin Immunol. 2004;14:329-34.
148. Schubert B, Grosse Perdekamp MT, Pfeuffer P, et al. Non-steroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol. 2005;15:164-7.
149. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, dagnosis, and management. J Allergy Clin Immunol. 2003;111:913-21.
150. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
151. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-8.
152. ACR manual on contrast media, version 7. ACR committee on drugs and contrast media. American College of Radiology; 2010
153. Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009;64:234-41.
154. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293-352.
155. ESUR guidelines on contrast media. European society of urogenital radiology, version 7.0 view. http://www.esur.org/Contrast-media.51.0.html
156. Morcos SK. Acute serious and fatal reactions to contrast media: our current understanding. Br J Radiol. 2005;78:686-93.
157. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol. 1996;167:847-9.
158. Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196:W138-43.
159. Thomsen HS. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol. 2007;17:2692-6.
160. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am. 2009;47:827-31.
161. Trcka J, Schmidt C, Seitz CS, et al. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol. 2008; 190:666-70.
162. Webb JAW, Stacul F, Thomsen HS, et al. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol. 2003;13:181-4.
163. Barnes E, Salio M, Cerundolo V, et al. Impact of alpha interferon and ribaviron on the function of maturing dendritic cells. Antimicrob Agents Chemother. 2004; 48:3382-9.
164. Bernardes GJL, Casi G, Trussel S, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed. 2012;51:941-4.
165. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98: 1315-24.
166. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725-32.
167. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109-17.
168. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39: 788-97.
169. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65:6-12.
170. 389 IL-2 (denileukin diftitox, Ontak®) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001;1: 298-302.
171. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325-38.
172. Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs. 2011;25:1-11.
173. Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010;31:1198-207.
174. Reichert JM. Which are the antibodies to watch in 2012? MAbs. 2012;4:1-3.
175. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278-87.
176. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13:235-44.
177. Shim H. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. 2011;43:539-49.
178. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-24.
179. Baeck M, Chemelle J-A, Terreux R, et al. Delayed hypersensitivity to corticosteroids in a series of 315 patients: clinical data and patch test results. Contact Dermatitis. 2009;61:163-75.
180. Baeck M, Goossens A. Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis. 2011;66:38-45.
181. Boffa MJ, Wilkinson SM, Beck MH. Screening for corticosteroid contact hypersensitivity. Contact Dermatitis. 1995;33:149-51.
182. Burgdorff T, Venemalm L, Vogt T, et al. IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol. 2002;89:425-8.
183. Lauerma AI. Contact hypersensitivity to glucocorticosteroids. Dermatitis. 1992;3:112-32.
184. Nancey S, Freymond N, Catelain A, et al. Effects of local corticosteroids on acute experimental urticaria. Eur J Dermatol. 2004;14:323-6.
185. Wilkinson SM. Corticosteroid cross-reactions: an alternative view. Contact Dermatitis. 2000;42:59-63.
186. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315: 971-9.
187. Balagula Y, Lacouture ME, Cotliar A. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol. 2010;8:149-61.
188. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-77. Common terminology criteria for adverse events v3.0, DTCD, NCI, NIH, DHHS. Publish date: August 9, 2006 (http:/cstep.cancer.gov).
189. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer. 2004;100:228-37.
190. Curtis BR, Kaliszewski J, Marques MB, Wasif Saif M, Nabelle L, Blank J, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006;81:193-8.
191. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808-17.
192. Guastalla JP, Diéras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003;89 Suppl 3:S16-22.
193. Hannon MJ. Metal-based anticancer drugs: from a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure Appl Chem. 2007;79:2243-61.
194. Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-54.
195. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346:645-52.
196. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol. 2012;19:99-115.
197. Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601-9.
198. Levitzki A, Klein S. Signal transduction therapy of cancer. Mol Aspects Med. 2010;31:287-329.
199. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004;25:53-64.
200. Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor - associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610-21.
201. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141-5.
202. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: ten years later. Blood. 2012;120:947-59.
203. Nelson Jr RP, Cornetta K, Ward KE, et al. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol. 2006;97:216-22.
204. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am. 2010;94:835-52.
205. Tanaka K. The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85:12-36.
206. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4: 307-20.
207. Wong M, Grossman J, Hahn BH, La Cava A. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol. 2008;129:3-9.
208. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol. 2012;52:549-73.
209. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. Clin Oncol. 2001;19:3126-9.
210. Bonadonna P, Lombardo C, Bortolami O, et al. Hypersensitivity to proton pump inhibitors: diagnostic accuracy of skin tests compared to oral provocation test. J Allergy Clin Immunol. 2012;130:547-9.
211. Chang YS. Hypersensitivity reactions to proton pump inhibitors. Curr Opin Allergy Clin Immunol. 2012;12: 348-53.
212. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors - where do we stand in 2012? World J Gastroenterol. 2012;18:2161-71.
213. Eurich DT, Sadowski CA, Simpson SH, et al. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123:47-53.
214. Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70:101.
215. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2-8.